1. The Cyprus Institute of Neurology and Genetic
  2. Welcome
  3. Academic Staff
  4. Marios Phylactides
Back to Staff List
Marios Phylactides

Academic Staff

Current Position

Scientist, Molecular Genetics Thalassemia Department

The Cyprus Institute of Neurology & Genetics

Education

  • London Business School (LBS), Masters in Business Administration
  • University of London, University College, PhD in Molecular Immunology 
  • University of London, Imperial College, BSc (Hons) Biochemistry 

 

Research Interests

  • Genotype/phenotype correlation studies for β-thalasemia and HbH-disease patients
  • Reactivation of fetal hemoglobin by pharmacological agents for the treatment of β-hemoglobinpathies 
  • Investigation of the mechanism of action of HbF inducers through proteomic studies 
  • Studies on the molecular basis of non-deletional hereditary persistence of fetal hemoglobin 
  • Investigation of unusual cases of β-type hemoglobinopathies
  • Investigation of the effect of metals on the HbF inducing action of hydroxyurea

 

Biography

  1. Voskou S, Aslan M, Fanis P, Phylactides M, Kleanthous M. Oxidative stress in β-thalassaemia and sickle cell disease. Redox Biol. 2015 Dec;6:226-39. 
  2. Fanis P, Kousiappa I, Phylactides M, Kleanthous M. Genotyping of BCL11A and HBS1L-MYB SNPs associated with fetal haemoglobin levels: a SNaPshot minisequencing approach. BMC Genomics. 2014 Feb 6;15:108. 
  3. Kyrri AR, Kalogerou E, Loizidou D, Ioannou C, Makariou C, Kythreotis L, Phylactides M, Kountouris P, Angastiniotis M, Modell B, Kleanthous M. The changing epidemiology of β-thalassemia in the Greek-Cypriot population. Hemoglobin. 2013;37(5):435-43. 
  4. Borg J, Phylactides M, Bartsakoulia M, Tafrali C, Lederer C, Felice AE, Papachatzopoulou A, Kourakli A, Stavrou EF, Christou S, Hou J, Karkabouna S, Lappa-Manakou C, Ozgur Z, van Ijcken W, von Lindern M, Grosveld FG, Georgitsi M, Kleanthous M, Philipsen S, Patrinos GP. KLF10 gene expression is associated with high fetal hemoglobin levels and with response to hydroxyurea treatment in β-hemoglobinopathy patients. Pharmacogenomics. 2012 Oct;13(13):1487-500. doi: 10.2217/pgs.12.125.
  5. Borg J, Phylactides M, Bartsakoulia M, Tafrali C, Lederer C, Felice AE, Papachatzopoulou A, Kourakli A, Stavrou EF, Christou S, Hou J, Karkabouna S, Lappa-Manakou C, Ozgur Z, van Ijcken W, von Lindern M, Grosveld FG, Georgitsi M, Kleanthous M, Philipsen S, Patrinos GP. KLF10 gene expression is associated with high fetal hemoglobin levels and with response to hydroxyurea treatment in β-hemoglobinopathy patients. Pharmacogenomics. 2012 Oct;13(13):1487-500.
  6. Borg J, Papadopoulos P, Georgitsi M, Gutiérrez L, Grech G, Fanis P, Phylactides M, Verkerk AJ, van der Spek PJ, Scerri CA, Cassar W, Galdies R, van Ijcken W, Ozgür Z, Gillemans N, Hou J, Bugeja M, Grosveld FG, von Lindern M, Felice AE, Patrinos GP, Philipsen S. Haploinsufficiency for the erythroid transcription factor KLF1 causes hereditary persistence of fetal hemoglobin. Nat Genet. 2010 Sep;42(9):801-5.
  7. Spyrou P, Phylactides M, Lederer CW, Kithreotis L, Kirri A, Christou S, Kkolou E, Kanavakis E, Anagnou NP, Stamatoyannopoulos G, Kleanthous M. Compounds of the anthracycline family of antibiotics elevate human gamma-globin expression both in erythroid cultures and in a transgenic mouse model. Blood Cells Mol Dis. 2010 Mar-Apr;44(2):100-6.
  8. McCarthy VA, Ott CJ, Phylactides M, Harris A. Interaction of intestinal and pancreatic transcription factors in the regulation of CFTR gene expression. Biochim Biophys Acta. 2009 Nov-Dec;1789(11-12):709-18.
  9. Kyrri AR, Felekis X, Kalogerou E, Wild BJ, Kythreotis L, Phylactides M, Kleanthous M. Hemoglobin variants in Cyprus. Hemoglobin. 2009;33(2):81-94.
  10. Chassanidis C, Kalamaras A, Phylactides M, Pourfarzad F, Likousi S, Maroulis V, Papadakis MN, Vamvakopoulos NK, Aleporou-Marinou V, Patrinos GP, Kollia P. The Hellenic type of nondeletional hereditary persistence of fetal hemoglobin results from a novel mutation (g.-109G>T) in the HBG2 gene promoter. Ann Hematol. 2009 Jun;88(6):549-55
  11. Kleanthous M, Phylactides, M. Thalassemia and its relevance to personalized medicine. Personalized Medicine. 2008, 5(2),141-154, 2008
  12. Felekis X, Phylactides M, Drousiotou A, Christou S, Kyrri A, Kyriacou K, Kalogerou E, Christopoulos G, Kleanthous M. Hb Agrinio [alpha29 (B10) LeuPro (alpha2)] in Combination with - -(MED I) Results in a Severe Form of Hb H Disease. Hemoglobin 2008; 32(3): 237-46
  13. Pavlou E, Phylactides M, Kyrri A, Kalogerou E, Makariou C, Georgiou I, Kleanthous M. Delta-thalassaemia in Cyprus. Hemoglobin 2006; 30(4):455-62
  14. Mouchel N, Henstra SA, McCarthy VA, Williams SH, Phylactides M, Harris A. HNF1alpha is involved in tissue-specific regulation of CFTR gene expression. Biochem J. 2004 Mar 15;378(Pt 3):909-18.
  15. Phylactides M, Rowntree R, Nuthall H, Ussery D, Wheeler A, Harris A. Evaluation of potential regulatory elements identified as DNase I hypersensitive sites in the CFTR gene. Eur J Biochem. 2002 Jan;269(2):553-9.
  16. Rowntree RK, Vassaux G, McDowell TL, Howe S, McGuigan A, Phylactides M, Huxley C, Harris A. An element in intron 1 of the CFTR gene augments intestinal expression in vivo. Hum Mol Genet. 2001 Jul 1;10(14):1455-64. 
  17. Tkalcevic J, Novelli M, Phylactides M, Iredale JP, Segal AW, Roes J. Impaired immunity and enhanced resistance to endotoxin in the absence of neutrophil elastase and cathepsin G. Immunity. 2000 Feb;12(2):201-10.
  18. Phylactides M. Molecular biology series 3. Tools of molecular biology: gene cloning. Br J Hosp Med. 1997 Jan 15-Feb 5;57(1-2):49-50. 

Awards

Framework program for research, technological development and innovation 2009-2010 projects:

  • Genotype/phenotype correlation studies for HbH-disease patients and all the β-thalassemia patients in Cyprus. Call Identifier:    ΥΓΕΙΑ/ΔΥΓΕΙΑ/0311(ΒΙΕ)/39.  Total Project Budget: € 179928
  • Chemoinformatic solutions for the identification and optimization of agents for the treatment of thalassemia.  Call Identifier:   ΥΓΕΙΑ/ΒΙΟΣ/0609(ΒΙΕ)/13.Total project Budget: € 179936 
  • Screening and delineation of the molecular mechanism of action of novel agents for the treatment of β-thalassemia.  Call Identifier:   ΥΓΕΙΑ/ΒΙΟΣ/0609(ΒΕ)/01.Total project Budget: € 139948 
  • HU-Pharmgk: Pharmacogenomic analysis of β-thalassemia patients under Hydroxyurea treatment: Implications for β-thalassemia therapeutics, 2007-2009. RPF ΠΔΕ/0406 (79,200 CYP).
 
Fellowships:
UCL Special Trustees Fund fellowship for PhD students 
winner aashe copernicus